跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
NAT-GEFITINIB - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
NAT-GEFITINIB
Authorized
STANDARD
NAT-GEFITINIB
natco pharma (canada) inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
8e3d6b5b23ac1f2e
Company
natco pharma (canada) inc
Type
Standard
Approval Details
Approval Id
8e3d6b5b23ac1f2e
Drug Approval Canada Name
NAT-GEFITINIB
Product Name
NAT-GEFITINIB
Status
Marketed
Status Date
2019-11-13
Original Market Date
2019-11-13
Din
02491796
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EB01 GEFITINIB
Atc Name
l 01 eb 01
Aig Number
0149783001
Company Name
natco pharma (canada) inc
Company Address
2000 Argentia Road, Plaza 1, Suite 200, Mississauga, Ontario, Canada, L5N 1P7
Active Ingredients
GEFITINIB
250 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
8e3d6b5b23ac1f2e
Type
Standard
Back to Health Canada Approvals